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The vegetative state (VS), also known as “unresponsive wakefulness syndrome,” is 
considered one of the most devastating outcomes of acquired brain injury. While diag-
nosis of this condition is generally well-defined clinically, patients often appear to be 
awake despite an absence of behavioral signs of awareness, which to the family can 
be confusing, leading them to believe the loved one is aware of their surroundings. This 
inequality of agreement can be very distressing. Currently, no cure for the VS is available; 
as a result, patients may remain in this condition for the rest of their lives, which in some 
cases amount to decades. Recent advances in stem cell approaches for the treatment 
of other neurological conditions may now provide an opportunity to intervene in this 
syndrome. This mini review will address the development of VS, its diagnosis, affected 
cerebral structures, and the underlying basis of how stem cells can offer therapeutic 
promise that would take advantage of the often long-term features associated with this 
maladie to effect a repair of the severely damaged circuitry. In addition, current limitations 
of this treatment strategy, including a lack of animal models, few long-term clinical stud-
ies that might identify benefits of stem cell treatment, and the potential for development 
of tumors are considered.
Keywords: consciousness, neuroimaging, traumatic brain injury, hypoxia-ischemia, unresponsive wakefulness 
syndrome, stem cell, transplantation, induced pluripotent stem cell
inTRODUCTiOn
The diagnosis of “vegetative state” (VS) (1) assigned to patients following a severe injury to the brain 
is a devastating one. Originally, this condition was meant to indicate a complete lack of cortical 
functioning. However, a number of studies (2, 3) suggest that some VS patients possess at least ele-
ments of intact cognitive functions, e.g., pitch discrimination, or recognition of nonsensical sentence 
endings (3–6), and that following brain damage, some form of consciousness persists (7). Recently, 
VS has been termed an “unresponsive wakefulness syndrome” (8), in which patients may appear to 
be awake yet still not show behavioral signs of awareness. Indeed, some of these patients may start to 
show non-reflexive behavior, albeit inconsistently, e.g., gaze following, orienting responses, or com-
mand following. Such patients are then diagnosed as in a minimally conscious state (9). Correctly 
diagnosing these patients can be difficult, reflected in high rates of misdiagnoses (10).
In many countries, including the United States and Great Britain, the current prevalence of VS 
is unknown (11). However, in 1994, it was determined that as many as 10,000–25,000 U.S. adults 
and 4,000–10,000 children were diagnosed as being “awake but not aware” (12, 13). A recent sys-
tematic review of prevalence studies on VS revealed a wide variation in outcome of 0.2–6.1 patients 
per 100,000 members of the general population (14). In a nationwide study in the Netherlands, a 
prevalence of 0.1–0.2 hospitalized and institutionalized VS/UWS patients per 100,000 members of 
the general population was indicated (15).
FiGURe 1 | Traumatic head injury resulting in development of vS 
with subsequent bilateral cortical atrophy. Patient was admitted with 
extradural hematoma (A,D). Evacuation of hematoma relieved brain 
asymmetry (B,e). However, patient decompensated to a VS with delayed 
cerebral atrophy observed at 4 months post-op. Note enlarged sulci, 
particularly in the fronto-temporal lobes (C,F). Reproduced from Louzada 
et al. (65) with permission.
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Persistent VS has been defined as the condition remaining 
1 month after acute traumatic or non-traumatic brain injury (TBI) 
and it implies reversibility (12). However, VS which is 3 months 
after non-TBI or 12 months after TBI to all intents and purposes 
is regarded as a permanent VS, and it reflects irreversible injury of 
impaired consciousness. Currently, the official definition of per-
manent VS is based on the following seven diagnostic criteria: (1) 
no evidence of awareness of self or environment and an inability 
to interact with others; (2) no evidence of sustained, reproducible, 
purposeful, or voluntary behavioral responses to visual, auditory, 
tactile, or noxious stimuli; (3) no evidence of language compre-
hension or expression; (4) intermittent wakefulness manifested 
by the presence of sleep–wake cycles; (5) sufficiently preserved 
hypothalamic and brain stem autonomic functions to permit 
survival with medical and nursing care; (6) bowel and bladder 
incontinence; and (7) variably preserved cranial-nerve reflexes 
and spinal reflexes (12).
Development of the vS and its Diagnosis
Typically, VS develops as a consequence of hypoxic-ischemic 
encephalopathy in which the entire brain is involved, with 
cardiac/pulmonary arrest, strangulation, head injury, or near 
drowning being the causative factor (Figure  1). Brain swelling 
secondary to TBI is also a common cause of this global ischemia. 
The VS is usually preceded by a coma, with about 1–14% of cases 
developing clinical indicators of this condition, that include 
the presence of decorticate posturing, ventilatory dysfunction, 
and extraneural trauma shortly following the insult (7). Other 
features suggestive of a vegetative outcome include a poor motor 
response, advanced age, and an abnormal pupillary reflex. On the 
other hand, patients in non-traumatic comas display impaired 
eye opening, altered motor responses, and a loss of the ability to 
respond adequately to commands after 2 weeks, which together 
are highly suggestive of VS.
The diagnosis of VS is usually dependent on a number of 
investigations that include (i) bedside clinical evaluation, (ii) 
electroencephalographic (EEG) measurements, including event 
related potentials, a derivate of the EEG, which can be helpful in 
investigating cognitive processing and possibly conscious aware-
ness in VS patients, and (iii) functional neuroimaging that can 
include positron emission tomography which provides informa-
tion on cerebral metabolism and activation of particular brain 
regions, and functional magnetic resonance imaging, which can 
also identify brain activity in terms of increased local cerebral 
blood flow in response to sensory stimulation.
Cerebral Structures Associated with vS
Results of autopsy studies of patients in VS at the time of death 
have identified widespread neuronal death throughout the thala-
mus as the common finding following either anoxia or diffuse 
axonal injury that produces widespread disruption of white mat-
ter connections (16). The severe bilateral thalamic damage after 
either trauma or anoxia seen in permanent VS is not, however, 
invariably associated with diffuse neocortical neuronal cell death. 
Specific thalamic regions exhibit profound neuronal cell death as 
a consequence of brain trauma injuries, e.g., the central thalamic 
nuclei that include the intralaminar nuclei and paralaminar 
nuclei (17). Rostrocaudally, severe disability is reflected in the 
extent of neuronal cell death, in which severity of dysfunction 
progresses in the rostrocaudal direction, with the anterior 
intralaminar and surrounding areas at first exhibiting negative 
volume change that is linked to moderate disability, while damage 
to the posterior intralaminar nuclei is associated with increased 
disability, often seen in both VS and in minimally conscious 
patients (17). This large-scale neuronal loss in the thalamus is 
probably a consequence of severe cerebral injury mainly due to 
diffuse trauma, hypoxia, and other non-specific damage. Direct 
injury to the central thalamus leads to coma, indicating these cells 
are an important factor in the regulation of arousal (18). This part 
of the brain contains circuitry that has a key role to play in the 
sleep–wake cycle, involving the brain stem associated arousal 
system (18). It is also innervated by projections from the basal 
forebrain. Thus, these wiring influences can modulate the level 
of arousal associated with generalized alertness and variations 
in cognitive effort, stress, sleep deprivation, and other variables 
affecting the wakeful state (18, 19). In addition, studies have 
identified diffuse axonal injury in 70–80% of the studied brains, 
along with widespread damage to the white matter (20, 21).
Stem Cell-Mediated Therapeutic 
intervention in Patients with vS
Endogenous NSCs
Given that patients in VS can spend months, even years in this 
condition, an important consideration should be whether a stem 
cell treatment paradigm might be beneficial under these circum-
stances, taking advantage of the long-term condition of these 
cases. In recent years, a new approach to the treatment of disease 
has been developing, one that holds considerable potential for 
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large numbers of individuals in which damage to an organ is pres-
ently unrepairable with drugs, surgery, or other forms of therapy. 
The relatively recent discovery that in selected regions of the brain 
neurons can be produced during adult life has invigorated both 
scientists and the public, focusing interest on the possibility of 
manipulating the development of these endogenous neurogenic 
populations and utilising them for treating a variety of neurologi-
cal and neurodegenerative diseases. Studies have demonstrated 
that neurogenesis occurs throughout life but is mainly limited to 
the periventricular subventricular zone (SVZ), in which neurons 
develop that are destined for the olfactory bulb, and the subgranular 
zone (SGZ) of the hippocampus, in which new neurons are estab-
lished within the dentate gyrus (22, 23). Neural stem cells (NSCs) 
are an undifferentiated population of cells residing in the SVZ and 
SGZ of both the embryonic and adult mammalian brain (24–26). 
In the adult brain, pathological events, such as TBI (27), stroke 
(28), seizures (29, 30), and neuroinflammatory states (31), can 
stimulate neurogenesis, which can have a protective role. Evidence 
thus far suggests that while these cells show a positive response to 
the insult, the long-term beneficial effects are limited in nature. 
On the other hand, the response of these cells can be enhanced via 
exogenous means and augmentation of endogenous NSCs could 
therefore be a potential therapy for treating the injured brain. For 
example, basic fibroblast growth factor or epidermal growth factor 
can enhance TBI-induced cell proliferation in the hippocampus 
and the SVZ, and drastically improve cognitive functional recov-
ery (32, 33). In addition, several drugs have shown the potential 
to enhance neurogenesis and improve cognitive function in 
experimental TBI. These include statins (34), progesterone (35), 
erythropoietin (36, 37), and the antidepressant imipramine (38). 
Such studies lend credence to the notion that increasing the activ-
ity of endogenous NSCs may provide an important therapeutic 
approach for treating patients in VS.
Stem Cell Transplantation
Due to the limited repair potential available to the damaged brain, 
the prospect of neural transplantation represents an important 
and viable choice for the treatment of injured cerebral tissue 
(39). In addition to providing a substrate for the regeneration of 
circuitry lost by the insult, transplanted cells originating from 
different stem cell sources may also stimulate surviving circuitry 
to establish new synaptic connections by way of providing trophic 
support. Potential sources of these cells include adult NSCs, bone 
marrow cells, umbilical cord cells, and induced pluripotent stem 
cells (iPSCs).
Adult NSCs
In humans, multipotent stem/progenitor cells have been identi-
fied and successfully isolated from various regions of adult 
human brain, including the hippocampus, SVZ, neocortex, and 
subcortical white matter from neurosurgical resection tissue 
(40–42). These cells could potentially be used as an autologous 
cell source for transplantation therapy. Thus far, very few studies 
have examined the behavior of adult-derived human NSCs in the 
injured adult CNS. Previous studies have reported that 4% of adult 
human NSCs survive for 4 months following transplantation in 
rats with hippocampal damage due to ischemia (43). However, 
whether these cells become properly integrated with the existing 
circuitry remains unclear. Another concern as to the potential 
use of these cells in terms of their translational value relates to 
the possibility of tumor development, which could have negative 
ramifications regarding their future use in a clinical setting. On 
the other hand, use of autologous transplantation as an option, 
involving the neurosurgical isolation of NSCs from patients with 
head injury cannot be disregarded and needs to be fully engaged 
as a viable option. However, whether these cells remain viable 
for a significant period of time post-surgery while retaining the 
capacity to improve functional outcome in patients with VS 
remains an unanswered question that needs to be addressed in 
the future.
Bone Marrow Cells
Mesenchymal bone marrow stromal cells (BMSCs) are a mix-
ture of undifferentiated cells that includes stem and progenitor 
cells. Their ability for self-renewal and multipotential capability 
provides for applications in tissue engineering and regenerative 
medicine. These cells can be readily isolated from bone marrow 
and grown in culture without ethical and technical concerns. 
Several studies have reported that transplanted BMSCs acceler-
ate neuroplasticity and facilitate neuronal regeneration and 
functional recovery (44–47). In addition, they exhibit an ability 
to enhance the proliferation of endogenous NSCs (48). Such 
attributes make them an attractive candidate for the treatment 
of VS, particularly given their low antigenicity due to reduced 
expression of the major histocompatibility complex (class II) 
antigens (49). These cells produce high levels of growth factors, 
cytokines, and extracellular matrix molecules that could have 
potential neurotrophic or neuroprotective effect in the injured 
brain. Indeed, studies have demonstrated that the beneficial 
effects of transplanted BMSCs are attributed to their neurotrophic 
or neuroprotective effect rather than direct cell replacement (50).
Transplantation of human BMSCs into rats following TBI led 
to an improvement in sensorimotor and spatial learning along 
with a reduction in brain injury volume and improved angiogen-
esis (51, 52). This improved sensorimotor function was evident 
even when treatment with these cells was delayed by 2 months 
following brain injury (53), indicative of the long-term viability 
of these cells and their ability to ameliorate the extent of cerebral 
damage following administration at later times. This suggests 
that treatment of cases of VS with these cells has the potential to 
benefit patients even if treatment is delayed following the insult. 
In a recent study, 45% of cases of VS treated with autologous 
BMSCs showed an improvement in consciousness (54). Allogenic 
transplantation of hematopoietic stem cells (HSCs) from bone 
marrow has also been promising in the treatment of X-linked 
adrenoleukodystrophy (ALD), a progressive disease presenting 
most commonly in males, in which cerebral demyelination due 
to improper fatty acid metabolism in early childhood can rapidly 
lead to a VS (55). Autologous treatment of HSCs in combination 
with gene therapy, involving an introduction of wild-type cDNA 
of the mutated gene into these cells has provided additional 
benefits for young children with ALD, in which arrest of cerebral 
demyelination was achieved (56). Altogether, these findings 
support the idea that BMSCs provide an important potential for 
FiGURe 2 | The patient (L.B.) before and after autologous umbilical cord blood transplantation. (A) The patient during EEG recording is in a VS 9 weeks 
after the insult before transplantation of cord blood cells. Note the dilated, unresponsive pupils in spite of bright light from the ceiling. (a–c) Two-month follow-up. 
(a) First social smiling of the patient (L.B.) toward his mother and (b,c) laughing, when played with, 2 months after transplantation of cord blood cells (i.e., 4 months 
and 1 week after severe brain damage caused by cardiac arrest). Reproduced from Jensen and Hamelmann (58) with permission.
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treatment of the injured brain and strongly points to benefits 
from BMSC treatment, highlighting the notion for future use of 
these cells in the treatment of VS.
Umbilical Cord Blood
Several key features make umbilical cord blood an attractive 
prospect for treatment of VS. Cord blood provides large num-
bers of HSCs, mesenchymal stem cells, unrestricted somatic 
stem cells, and embryonic-like stem cells. These cells can be 
easily harvested at birth without ethical controversy, can be 
administered with no risk of allograft rejection, and without 
ethical complications (57). In a landmark study, autologous 
intravenous cord blood transplantation in a two and a half 
year old child was shown to considerably improve neurologic 
function over a period of 40  months following cardiac arrest 
and development of VS, representing the first reported case of 
a successful cell therapy treatment of pediatric cerebral palsy 
(58) (Figure 2). In an earlier report, treatment of a 16-month-
old child in VS with cord blood led to lesser though significant 
clinical improvement over a 6-month period (59). In addition, 
allogenic cord blood treatment of an 8-year-old boy with 
ALD prevented neurological deterioration and halted disease 
progression (60). Notably, one study involving an 8-month-old 
infant in VS suggests that it may be possible to influence the 
movement of these cells in the brains of such patients when 
labeled with paramagnetic iron oxide particles and using an 
external magnetic field following their transplantation into 
the ventricular system (61). Such an approach could be useful 
in helping to direct transplanted stem cells toward the site of 
a lesion. These findings strengthen the case that it is possible 
to use stem cells as a viable, major therapeutic strategy for the 
treatment of patients in VS, one that should be engaged, not 
ignored.
Induced Pluripotent Stem Cells
The development of iPSCs (62), involving somatic cell reprogram-
ing, represents an important watershed, providing the potential 
for novel neural replacement strategies. The main characteristics 
of iPSCs are unlimited self-renewal and pluripotency (63), 
defining the ability to differentiate into three germ layers and 
multilineage cell types. Significantly, a major advantage of the use 
of patient-specific iPSCs is that it can be safely administered as 
an autologous treatment without the potential for rejection. Such 
properties of these reprogramed cells help provide considerable 
hope that VS and other disease states in which neurodegeneration 
is a feature might be successfully treated in the future. Indeed, in 
the 10 years since the seminal work of Takahashi and Yamanaka 
(62), significant progress has already occurred in deriving iPSCs 
suitable for clinical use (64).
COnCLUSiOn
For decades, the VS has been considered to represent a severe 
neurological condition, recovery from which was extremely 
unlikely, if at all. Patients might remain in this condition for 
years without much chance for significant recovery. However, 
recent advances in our understanding of the ability of stem cells 
to positively influence repair of the damaged brain suggests 
that the VS may no longer be the largely irreversible maladie 
of years past. Although in the absence of an established animal 
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